Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-alanosine in MTAP-Deficient Cancer
NCT00062283Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2003
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alanosine in soft tissue sarcoma (STS), osteosarcoma (OS), chondrosarcoma and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Response Rate. Started Mar 2003; status: completed.
02
Drugs
alanosine
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)chondrosarcomamalignant mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00062283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062283.